MADRIGAL PHARMACEUTICALS INC. - COMMON STOCK

Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis

21 أكتوبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024

18 أكتوبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference

02 أكتوبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development

01 أكتوبر 2024 08:00:01 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra™ (resmetirom)

30 سبتمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

26 أغسطس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates

07 أغسطس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel

02 أغسطس 2024 07:00:21 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024

24 يوليو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress

06 يونيو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress

29 مايو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

07 مايو 2024 07:00:01 بحسب Nasdaq GlobeNewswire

Madrigal Statement on the Passing of Dr. Stephen Harrison

24 أبريل 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024

23 أبريل 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

16 أبريل 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis

09 أبريل 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 أبريل 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering

18 مارس 2024 23:58:56 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Proposed Public Offering

18 مارس 2024 16:04:05 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis

14 مارس 2024 16:15:00 بحسب Nasdaq GlobeNewswire